OpenLB
Open Library of Bioscience
Advanced Search
Journal of neural transmission (Vienna, Austria : 1996)
Mar 22, 2025;

Real-world experience with continuous subcutaneous foslevodopa/foscarbidopa infusion: insights and recommendations.

Thomas Koeglsperger, Emir Berberovic, Christian Dresel, Sebastian Haferkamp, Jan Kassubek, Rahel Müller, Christian Oehlwein, Sebastian Paus, Peter Paul Urban
Author Information
  1. Thomas Koeglsperger: Department of Neurology, LMU University Hospital, LMU Munich, Munich, Germany. thomas.koeglsperger@med.uni-muenchen.de.
  2. Emir Berberovic: Parkinson-Klinik Ortenau, Wolfach, Germany.
  3. Christian Dresel: Department of Neurology, University Medical Center Mainz, Johannes Gutenberg University, Mainz, Germany.
  4. Sebastian Haferkamp: Department of Dermatology, University Hospital Regensburg, Regensburg, Germany.
  5. Jan Kassubek: Department of Neurology, University Hospital Ulm, Ulm, Germany.
  6. Rahel Müller: Department of Neurology, University Hospital Augsburg, Augsburg, Germany.
  7. Christian Oehlwein: Neurology Private Practice, Gera, Germany.
  8. Sebastian Paus: Department of Neurology, GFO Kliniken Troisdorf, Troisdorf, Germany.
  9. Peter Paul Urban: Department of Neurology, Asklepios Klinik Barmbek, Hamburg, Germany.
PMID: 40121314 DOI: 10.1007/s00702-025-02911-5

Abstract

Traditional advanced therapies in Parkinson's disease (PD) with motor fluctuations and dyskinesias like continuous apomorphine infusion (CSAI), levodopa-carbidopa intestinal gel (LCIG), levodopa-carbidopa entacapone intestinal gel (LECIG), or deep brain stimulation (DBS) have played a central role in managing therapy-related complications. Recently, continuous subcutaneous foslevodopa/foscarbidopa infusion (CSFLI) has emerged as a novel therapeutic option. This manuscript provides insights from one year of real-world experience with CSFLI, addressing critical questions that clinicians face when selecting the most appropriate therapy for advanced PD. Our discussion centers on key considerations for patient selection, exploring which individuals may benefit more from CSFLI compared to other device-aided therapies. We highlight CSFLI's advantages in flexibility and ease of use but also consider limitations, particularly its side effects, such as skin-related issues. Recommendations are presented on how to prevent and manage these adverse effects to maximize patient compliance and therapeutic success. Additionally, the paper examines strategies for optimizing concurrent oral medications when combined with CSFLI, providing guidance on balancing pump infusion with necessary adjunctive oral treatments.

Keywords

Advanced Treatment Foslevodopa/Foscarbidopa Motor Fluctuations Parkinson’s disease

References

Abboud H, Floden D, Thompson NR et al (2015) Impact of mild cognitive impairment on outcome following deep brain stimulation surgery for Parkinson’s disease. Park Relat Disord 21:249–253. https://doi.org/10.1016/j.parkreldis.2014.12.018 [DOI: 10.1016/j.parkreldis.2014.12.018]
Acland KM, Churchyard A, Fletcher CL et al (1998) Panniculitis in association with apomorphine infusion. Br J Dermatol 138:480–482. https://doi.org/10.1046/j.1365-2133.1998.02128.x [DOI: 10.1046/j.1365-2133.1998.02128.x]
Aldred J, Freire-Alvarez E, Amelin AV et al (2023) Continuous Subcutaneous Foslevodopa/Foscarbidopa in Parkinson’s disease: safety and efficacy results from a 12-month, single-arm, open-label, phase 3 study. Neurol Ther 12:1937–1958. https://doi.org/10.1007/s40120-023-00533-1 [DOI: 10.1007/s40120-023-00533-1]
Alegret M, Valldeoriola F, Martí M et al (2004) Comparative cognitive effects of bilateral subthalamic stimulation and subcutaneous continuous infusion of apomorphine in Parkinson’s disease. Mov Disord 19:1463–1469. https://doi.org/10.1002/mds.20237 [DOI: 10.1002/mds.20237]
Antonini A, Isaias IU, Rodolfi G et al (2011) A 5-year prospective assessment of advanced Parkinson disease patients treated with subcutaneous apomorphine infusion or deep brain stimulation. J Neurol 258:579–585. https://doi.org/10.1007/s00415-010-5793-z [DOI: 10.1007/s00415-010-5793-z]
Antonini A, Poewe W, Chaudhuri KR et al (2017) Levodopa-carbidopa intestinal gel in advanced Parkinson’s: Final results of the GLORIA registry. Park Relat Disord 45:13–20. https://doi.org/10.1016/j.parkreldis.2017.09.018 [DOI: 10.1016/j.parkreldis.2017.09.018]
Antonini A, Stoessl AJ, Kleinman LS et al (2018) Developing consensus among movement disorder specialists on clinical indicators for identification and management of advanced Parkinson’s disease: a multi-country Delphi-panel approach. Curr Med Res Opin 34:2063–2073. https://doi.org/10.1080/03007995.2018.1502165 [DOI: 10.1080/03007995.2018.1502165]
Artusi CA, Geroin C, Nonnekes J et al (2023) Predictors and pathophysiology of axial postural abnormalities in parkinsonism: a scoping review. Mov Disord Clin Pr 10:1585–1596. https://doi.org/10.1002/mdc3.13879 [DOI: 10.1002/mdc3.13879]
Barbosa ENB, Fichman HC (2019) How is cognition in subthalamic nucleus deep brain stimulation Parkinson’s disease patients? Dement Neuropsychol 13:367–377. https://doi.org/10.1590/1980-57642018dn13-040002 [DOI: 10.1590/1980-57642018dn13-040002]
Bergquist F, Ehrnebo M, Nyholm D et al (2024) Motor efficacy of subcutaneous DIZ102, intravenous DIZ101 or intestinal levodopa/carbidopa infusion. Mov Disord Clin Pr 11:1095–1102. https://doi.org/10.1002/mdc3.14138 [DOI: 10.1002/mdc3.14138]
Bergquist F, Ehrnebo M, Nyholm D, et al (2022) Pharmacokinetics of intravenously (DIZ101), subcutaneously (DIZ102), and intestinally (LCIG) infused levodopa in advanced parkinson disease. Neurology 99:e965–e976. https://doi.org/10.1212/WNL.0000000000200804 .
Bhidayasiri R, Sringean J, Anan C et al (2016) Quantitative demonstration of the efficacy of night-time apomorphine infusion to treat nocturnal hypokinesia in Parkinson’s disease using wearable sensors. Park Relat Disord 33:S36–S41. https://doi.org/10.1016/j.parkreldis.2016.11.016 [DOI: 10.1016/j.parkreldis.2016.11.016]
Bonuccelli U, Piccini P, Corsini GU, Muratorio A (1992) Apomorphine in malignant syndrome due to levodopa withdrawal. Ital J Neurol Sci 13:169–170. https://doi.org/10.1007/bf02226968 [DOI: 10.1007/bf02226968]
Borgemeester RWK, Drent M, van Laar T (2016) Motor and non-motor outcomes of continuous apomorphine infusion in 125 Parkinson’s disease patients. Park Relat Disord 23:17–22. https://doi.org/10.1016/j.parkreldis.2015.11.013 [DOI: 10.1016/j.parkreldis.2015.11.013]
Boura I, Haliasos N, Giannopoulou Ι et al (2021) Combining device-aided therapies in parkinson’s disease: a case series and a literature review. Mov Disord Clin Pr 8:750–757. https://doi.org/10.1002/mdc3.13228 [DOI: 10.1002/mdc3.13228]
Bove F, Fraix V, Cavallieri F et al (2020) Dementia and subthalamic deep brain stimulation in Parkinson disease: A long-term overview. Neurology 95:e384–e392. https://doi.org/10.1212/wnl.0000000000009822 [DOI: 10.1212/wnl.0000000000009822]
Carbone F, Djamshidian A, Seppi K, Poewe W (2019) Apomorphine for Parkinson’s Disease: efficacy and safety of current and new formulations. CNS Drugs 33:905–918. https://doi.org/10.1007/s40263-019-00661-z [DOI: 10.1007/s40263-019-00661-z]
Caroff SN, Jain R, Morley JF (2020) Revisiting amantadine as a treatment for drug-induced movement disorders. Ann Clin Psychiatr 32:198–208
Catalan MJ, Molina-Arjona JA, Mir P et al (2018) Improvement of impulse control disorders associated with levodopa–carbidopa intestinal gel treatment in advanced Parkinson’s disease. J Neurol 265:1279–1287. https://doi.org/10.1007/s00415-018-8803-1 [DOI: 10.1007/s00415-018-8803-1]
Cattaneo C, Ferla RL, Bonizzoni E, Sardina M (2015) Long-term effects of safinamide on dyskinesia in mid- to late-stage parkinson’s disease: a post-hoc analysis. J Park’s Dis 5:475–481. https://doi.org/10.3233/jpd-150569 [DOI: 10.3233/jpd-150569]
Cavallieri F, Fraix V, Bove F et al (2021) Predictors of long-term outcome of subthalamic stimulation in parkinson disease. Ann Neurol 89:587–597. https://doi.org/10.1002/ana.25994 [DOI: 10.1002/ana.25994]
Chambi CT, Rossi M, Bril A et al (2017) Diagnostic value of combined acute levodopa challenge and olfactory testing to predict Parkinson’s disease. Mov Disord Clin Pr 4:824–828. https://doi.org/10.1002/mdc3.12517 [DOI: 10.1002/mdc3.12517]
Chaudhuri KR, Ellis C, Love-Jones S et al (1997) Postprandial hypotension and parkinsonian state in parkinson’s disease. Mov Disord 12:877–884. https://doi.org/10.1002/mds.870120608 [DOI: 10.1002/mds.870120608]
Chaudhuri KR, Kovács N, Pontieri FE et al (2023) Levodopa carbidopa intestinal gel in advanced Parkinson’s Disease: DUOGLOBE final 3-year results. J Park’s Dis 13:769–783. https://doi.org/10.3233/jpd-225105 [DOI: 10.3233/jpd-225105]
Christmas TJ, Chapple CR, Lees AJ et al (1988) Role of subcutaneous apomorphine in parkinsonian voiding dysfunction. The Lancet 332:1451–1453. https://doi.org/10.1016/s0140-6736(88)90932-4 [DOI: 10.1016/s0140-6736(88)90932-4]
Cock VCD, Dodet P, Leu-Semenescu S et al (2022) Safety and efficacy of subcutaneous night-time only apomorphine infusion to treat insomnia in patients with Parkinson’s disease (APOMORPHEE): a multicentre, randomised, controlled, double-blind crossover study. The Lancet Neurol 21:428–437. https://doi.org/10.1016/s1474-4422(22)00085-0 [DOI: 10.1016/s1474-4422(22)00085-0]
Dafotakis M, Sparing R, Juzek A et al (2009) Transdermal dopaminergic stimulation with rotigotine in Parkinsonian akinetic crisis. J Clin Neurosci 16:335–337. https://doi.org/10.1016/j.jocn.2008.02.015 [DOI: 10.1016/j.jocn.2008.02.015]
Dafsari HS, Martinez-Martin P, Rizos A et al (2019) EuroInf 2: Subthalamic stimulation, apomorphine, and levodopa infusion in Parkinson’s disease. Mov Disord 34:353–365. https://doi.org/10.1002/mds.27626 [DOI: 10.1002/mds.27626]
Dean MN, Standaert DG (2024) Levodopa infusion therapies for Parkinson disease. Curr Opin Neurol 37:409–413. https://doi.org/10.1097/wco.0000000000001277 [DOI: 10.1097/wco.0000000000001277]
Denny AP, Behari M (1999) Motor fluctuations in Parkinson’s disease. J Neurol Sci 165:18–23. https://doi.org/10.1016/s0022-510x(99)00052-0 [DOI: 10.1016/s0022-510x(99)00052-0]
Deuschl G, Follett KA, Luo P et al (2020) Comparing two randomized deep brain stimulation trials for Parkinson’s disease. J Neurosurg 132:1376–1384. https://doi.org/10.3171/2018.12.jns182042 [DOI: 10.3171/2018.12.jns182042]
Diaconu Ş, Irincu L, Ţînţ D, Falup-Pecurariu C (2023) Long-term effects of intrajejunal levodopa infusion on sleep in people with advanced Parkinson’s disease. Front Neurol 14:1105650. https://doi.org/10.3389/fneur.2023.1105650 [DOI: 10.3389/fneur.2023.1105650]
Ebersbach G, Poewe W (2018) „Medikamentös ausbehandelte Fluktuationen“ trotz „optimierter peroraler/transdermaler Therapie“ bei Morbus Parkinson: Versuch einer pragmatischen Definition. Aktuelle Neurol 45:665–671. https://doi.org/10.1055/a-0642-1737 [DOI: 10.1055/a-0642-1737]
Ebersbach G, Höglinger GU, Koeglsperger T, Poewe W (2024) Zustandsschwankungen bei der Parkinson-Krankheit jenseits von On-/Off-Fluktuationen. Dgneurologie 7:453–460. https://doi.org/10.1007/s42451-024-00700-0 [DOI: 10.1007/s42451-024-00700-0]
Elia AE, Dollenz C, Soliveri P, Albanese A (2012) Motor features and response to oral levodopa in patients with Parkinson’s disease under continuous dopaminergic infusion or deep brain stimulation. Eur J Neurol 19:76–83. https://doi.org/10.1111/j.1468-1331.2011.03437.x [DOI: 10.1111/j.1468-1331.2011.03437.x]
Espay AJ, Hauser RA, Dhall R et al (2024a) Safety and efficacy of IPX203 in Parkinson’s Disease: the RISE-PD open-label extension study. Mov Disord 39:428–432. https://doi.org/10.1002/mds.29685 [DOI: 10.1002/mds.29685]
Espay AJ, Ostrem JL, Formella AE, Tanner CM (2024b) Extended-release amantadine for OFF-related dystonia in Parkinson’s disease. Park Relat Disord 122:106088. https://doi.org/10.1016/j.parkreldis.2024.106088 [DOI: 10.1016/j.parkreldis.2024.106088]
Espay AJ, Stocchi F, Pahwa R et al (2024c) Safety and efficacy of continuous subcutaneous levodopa–carbidopa infusion (ND0612) for Parkinson’s disease with motor fluctuations (BouNDless): a phase 3, randomised, double-blind, double-dummy, multicentre trial. Lancet Neurol 23:465–476. https://doi.org/10.1016/s1474-4422(24)00052-8 [DOI: 10.1016/s1474-4422(24)00052-8]
Fabbri M, Barbosa R, Rascol O (2023) Off-time Treatment options for Parkinson’s disease. Neurol Ther 12:391–424. https://doi.org/10.1007/s40120-022-00435-8 [DOI: 10.1007/s40120-022-00435-8]
Fahn S (2015) The medical treatment of Parkinson disease from James Parkinson to George Cotzias. Mov Disord 30:4–18. https://doi.org/10.1002/mds.26102 [DOI: 10.1002/mds.26102]
Fasano A, Romito LM, Daniele A et al (2010) Motor and cognitive outcome in patients with Parkinson’s disease 8 years after subthalamic implants. Brain 133:2664–2676. https://doi.org/10.1093/brain/awq221 [DOI: 10.1093/brain/awq221]
Fasano A, García-Ramos R, Gurevich T et al (2023) Levodopa–carbidopa intestinal gel in advanced Parkinson’s disease: long-term results from COSMOS. J Neurol 270:2765–2775. https://doi.org/10.1007/s00415-023-11615-3 [DOI: 10.1007/s00415-023-11615-3]
Fernandez HH, Odin P, Standaert DG et al (2023) Healthcare resource utilization and device-aided therapy discussions with eligible patients across the Parkinson’s disease continuum: Revelations from the MANAGE-PD validation cohort. Park Relat Disord 116:105514. https://doi.org/10.1016/j.parkreldis.2023.105514 [DOI: 10.1016/j.parkreldis.2023.105514]
Fernández-Pajarín G, Sesar Á, Ares B et al (2021) Continuous subcutaneous apomorphine infusion before subthalamic deep brain stimulation: a prospective, comparative study in 20 patients. Mov Disord Clin Pract 8:1216–1224. https://doi.org/10.1002/mdc3.13338 [DOI: 10.1002/mdc3.13338]
Ferreira JJ, Lees A, Rocha J-F et al (2016) Opicapone as an adjunct to levodopa in patients with Parkinson’s disease and end-of-dose motor fluctuations: a randomised, double-blind, controlled trial. Lancet Neurol 15:154–165. https://doi.org/10.1016/s1474-4422(15)00336-1 [DOI: 10.1016/s1474-4422(15)00336-1]
Ferreira JJ, Lees A, Rocha J-F et al (2019) Long-term efficacy of opicapone in fluctuating Parkinson’s disease patients: a pooled analysis of data from two phase 3 clinical trials and their open-label extensions. Eur J Neurol 26:953–960. https://doi.org/10.1111/ene.13914 [DOI: 10.1111/ene.13914]
Fietzek UM, Messner M, Levin J (2023) Kann KI Parkinson? Nervenheilkunde 42:612–620. https://doi.org/10.1055/a-2133-1575 [DOI: 10.1055/a-2133-1575]
Fiore S, Persichino L, Anticoli S, Pandis MFD (2014) A neuroleptic malignant-like syndrome (NMLS) in a patient with Parkinson’s disease resolved with rotigotine: a case report. Acta BioMed 85:281–284 [PMID: 25567468]
Franke C, Storch A (2017) Chapter thirty-three nonmotor fluctuations in Parkinson’s disease. Int Rev Neurobiol 134:947–971. https://doi.org/10.1016/bs.irn.2017.05.021 [DOI: 10.1016/bs.irn.2017.05.021]
Fujimiya M, Ataka K, Asakawa A et al (2011) Ghrelin, des-acyl ghrelin and obestatin on the gastrointestinal motility. Peptides 32:2348–2351. https://doi.org/10.1016/j.peptides.2011.07.020 [DOI: 10.1016/j.peptides.2011.07.020]
Gaspari DD, Siri C, Landi A et al (2006) Clinical and neuropsychological follow up at 12 months in patients with complicated Parkinson’s disease treated with subcutaneous apomorphine infusion or deep brain stimulation of the subthalamic nucleus. J Neurol Neurosurg Psychiatr 77:450. https://doi.org/10.1136/jnnp.2005.078659 [DOI: 10.1136/jnnp.2005.078659]
Gordon PH, Frucht SJ (2001) Neuroleptic malignant syndrome in advanced Parkinson’s disease. Mov Disord 16:960–962. https://doi.org/10.1002/mds.1166 [DOI: 10.1002/mds.1166]
Greulich W, Fenger E (1995) Amantadine in Parkinson’s disease: pro and contra. J Neural Transm Suppl 46:415–421 [PMID: 8821077]
Healy S, Shepherd H, Mooney N et al (2022) The effect of deep brain stimulation on impulse control related disorders in Parkinson’s disease – A 10-year retrospective study of 137 patients. J Neurol Sci 440:120339. https://doi.org/10.1016/j.jns.2022.120339 [DOI: 10.1016/j.jns.2022.120339]
Hechtner MC, Vogt T, Zöllner Y et al (2014) Quality of life in Parkinson’s disease patients with motor fluctuations and dyskinesias in five European countries. Park Relat Disord 20:969–974. https://doi.org/10.1016/j.parkreldis.2014.06.001 [DOI: 10.1016/j.parkreldis.2014.06.001]
Hillen ME, Sage JI (1996) Nonmotor fluctuations in patients with Parkinson’s disease. Neurology 47:1180–1183. https://doi.org/10.1212/wnl.47.5.1180 [DOI: 10.1212/wnl.47.5.1180]
Höglinger G (2023) DGN S2k Leitlinie Parkinson-Krankheit
Honig H, Antonini A, Martinez-Martin P et al (2009) Intrajejunal levodopa infusion in Parkinson’s disease: A pilot multicenter study of effects on nonmotor symptoms and quality of life. Mov Disord 24:1468–1474. https://doi.org/10.1002/mds.22596 [DOI: 10.1002/mds.22596]
Huh YE, Seo D-W, Kim K et al (2022) Factors contributing to the severity and laterality of pisa syndrome in Parkinson’s disease. Front Aging Neurosci 13:716990. https://doi.org/10.3389/fnagi.2021.716990 [DOI: 10.3389/fnagi.2021.716990]
Hung SW, Adeli GM, Arenovich T et al (2010) Patient perception of dyskinesia in Parkinson’s disease. J Neurol, Neurosurg Psychiatry 81:1112. https://doi.org/10.1136/jnnp.2009.173286 [DOI: 10.1136/jnnp.2009.173286]
Imbalzano G, Rinaldi D, Calandra-Buonaura G et al (2023) How resistant are levodopa-resistant axial symptoms? Response of freezing, posture, and voice to increasing levodopa intestinal infusion rates in Parkinson disease. Eur J Neurol 30:96–106. https://doi.org/10.1111/ene.15558 [DOI: 10.1111/ene.15558]
Investigators PSGCC (2009) Long-term effect of initiating Pramipexole vs Levodopa in early Parkinson disease. Arch Neurol 66:563–570. https://doi.org/10.1001/archneurol.2009.32 [DOI: 10.1001/archneurol.2009.32]
Jost ST, Kaldenbach M, Antonini A et al (2023a) Levodopa dose equivalency in Parkinson’s disease: updated systematic review and proposals. Mov Disord 38:1236–1252. https://doi.org/10.1002/mds.29410 [DOI: 10.1002/mds.29410]
Jost WH, Kulisevsky J, LeWitt PA (2023b) Inhaled levodopa for threatening impending OFF episodes in managing Parkinson’s disease. J Neural Transm 130:821–826. https://doi.org/10.1007/s00702-023-02636-3 [DOI: 10.1007/s00702-023-02636-3]
Kipps CM, Fung VSC, Grattan-Smith P et al (2005) Movement disorder emergencies. Mov Disord 20:322–334. https://doi.org/10.1002/mds.20325 [DOI: 10.1002/mds.20325]
Kornhuber J, Weller M, Riederer P (1993) Glutamate receptor antagonists for neuroleptic malignant syndrome and akitetic hyperthermic Parkinsonian crisis. J Neural Transm Park Dis Dement Sect 6:63–72. https://doi.org/10.1007/bf02252624 [DOI: 10.1007/bf02252624]
Kukkle PL, Garg D, Merello M (2023) Continuous subcutaneous infusion delivery of apomorphine in Parkinson’s disease: a systematic review. Mov Disord Clin Pr 10:1253–1267. https://doi.org/10.1002/mdc3.13810 [DOI: 10.1002/mdc3.13810]
Kuno S, Mizuta E, Yamasaki S (1997) Neuroleptic malignant syndrome in Parkinsonian patients: risk factors. Eur Neurol 38:56–59. https://doi.org/10.1159/000113484 [DOI: 10.1159/000113484]
Labeit B, Berkovich E, Claus I, et al (2022) Dysphagia for medication in Parkinson’s disease. npj Parkinsons Dis 8:156. https://doi.org/10.1038/s41531-022-00421-9
Leenders KL, Poewe WH, Palmer AJ et al (1986) Inhibition of L-{18F}fluorodopa uptake into human brain by amino acids demonstrated by positron emission tomography. Ann Neurol 20:258–262. https://doi.org/10.1002/ana.410200212 [DOI: 10.1002/ana.410200212]
Lees AJ, Ferreira J, Rascol O et al (2017) Opicapone as adjunct to levodopa therapy in patients with Parkinson disease and motor fluctuations: a randomized clinical trial. JAMA Neurol 74:197. https://doi.org/10.1001/jamaneurol.2016.4703 [DOI: 10.1001/jamaneurol.2016.4703]
Leta V, Dafsari HS, Sauerbier A et al (2021) Personalised advanced therapies in Parkinson’s disease: the role of non-motor symptoms profile. J Pers Med 11:773. https://doi.org/10.3390/jpm11080773 [DOI: 10.3390/jpm11080773]
Lhommée E, Klinger H, Thobois S et al (2012) Subthalamic stimulation in Parkinson’s disease: restoring the balance of motivated behaviours. Brain 135:1463–1477. https://doi.org/10.1093/brain/aws078 [DOI: 10.1093/brain/aws078]
Lhommée E, Wojtecki L, Czernecki V et al (2018) Behavioural outcomes of subthalamic stimulation and medical therapy versus medical therapy alone for Parkinson’s disease with early motor complications (EARLYSTIM trial): secondary analysis of an open-label randomised trial. Lancet Neurol 17:223–231. https://doi.org/10.1016/s1474-4422(18)30035-8
Lin F, Wu D, Yu J et al (2021) Comparison of efficacy of deep brain stimulation and focused ultrasound in parkinsonian tremor: a systematic review and network meta-analysis. J Neurology Neurosurg Psychiatry 92:434–443. https://doi.org/10.1136/jnnp-2020-323656 [DOI: 10.1136/jnnp-2020-323656]
Liu XD, Bao Y, Liu GJ (2019) Comparison between levodopa-carbidopa intestinal gel infusion and subthalamic nucleus deep-brain stimulation for advanced Parkinson’s disease: a systematic review and meta-analysis. Front Neurol 10:934. https://doi.org/10.3389/fneur.2019.00934 [DOI: 10.3389/fneur.2019.00934]
Loeffler MA, Mengel A, Single C, et al (2024) Subcutaneous foslevodopa in akinetic crisis. A case report from the neurological intensive care unit. Front Med 11:1446345. https://doi.org/10.3389/fmed.2024.1446345
Lopiano L, Modugno N, Marano P et al (2019) Motor and non-motor outcomes in patients with advanced Parkinson’s disease treated with levodopa/carbidopa intestinal gel: final results of the GREENFIELD observational study. J Neurol 266:2164–2176. https://doi.org/10.1007/s00415-019-09337-6 [DOI: 10.1007/s00415-019-09337-6]
Luquin M-R, Kulisevsky J, Martinez-Martin P, et al. (2017) Consensus on the definition of advanced Parkinson’s disease: a neurologists-based delphi study (CEPA Study). Parkinsons Dis 2017:4047392. https://doi.org/10.1155/2017/4047392
Margraf NG, Wrede A, Deuschl G, Schulz-Schaeffer WJ (2016) Pathophysiological concepts and treatment of camptocormia. J Park’s Dis 6:485–501. https://doi.org/10.3233/jpd-160836 [DOI: 10.3233/jpd-160836]
Martinez-Martin P, Schapira AHV, Stocchi F et al (2007) Prevalence of nonmotor symptoms in Parkinson’s disease in an international setting; study using nonmotor symptoms questionnaire in 545 patients. Mov Disord 22:1623–1629. https://doi.org/10.1002/mds.21586 [DOI: 10.1002/mds.21586]
Martinez-Martin P, Reddy P, Antonini A et al (2011) Chronic subcutaneous infusion therapy with apomorphine in advanced Parkinson’s disease compared to conventional therapy: a real life study of non motor effect. J Park Dis 1:197–203. https://doi.org/10.3233/jpd-2011-11037 [DOI: 10.3233/jpd-2011-11037]
Mendes-Bastos P, Simoes RM (2024) Algorithm for managing infusion site adverse events caused by subcutaneous foslevodopa/foscarbidopa and other device-aided therapies for advanced Parkinson’s Disease. Parkinsonism Relat Disord 107185. https://doi.org/10.1016/j.parkreldis.2024.107185
Merello M, Nouzeilles MI, Arce GP, Leiguarda R (2002) Accuracy of acute levodopa challenge for clinical prediction of sustained long-term levodopa response as a major criterion for idiopathic Parkinson’s disease diagnosis. Mov Disord 17:795–798. https://doi.org/10.1002/mds.10123 [DOI: 10.1002/mds.10123]
Merims D, Djaldetti R, Melamed E (2003) Waiting for ON: a major problem in patients with Parkinson disease and ON/OFF motor fluctuations. Clin Neuropharmacol 26:196. https://doi.org/10.1097/00002826-200307000-00009 [DOI: 10.1097/00002826-200307000-00009]
Merola A, Zibetti M, Angrisano S et al (2011) Comparison of subthalamic nucleus deep brain stimulation and Duodopa in the treatment of advanced Parkinson’s disease. Mov Disord 26:664–670. https://doi.org/10.1002/mds.23524 [DOI: 10.1002/mds.23524]
Moro E, Lang AE (2006) Criteria for deep-brain stimulation in Parkinson’s disease: review and analysis. Expert Rev Neurother 6:1695–1705. https://doi.org/10.1586/14737175.6.11.1695 [DOI: 10.1586/14737175.6.11.1695]
Nebe A, Ebersbach G (2009) Pain intensity on and off levodopa in patients with Parkinson’s disease. Mov Disord 24:1233–1237. https://doi.org/10.1002/mds.22546 [DOI: 10.1002/mds.22546]
Nutt JG, Woodward WR, Hammerstad JP et al (1984) The on–off phenomenon in Parkinson’s Disease — relation to levodopa absorption and transport. N Engl J Med 310:483–488. https://doi.org/10.1056/nejm198402233100802 [DOI: 10.1056/nejm198402233100802]
Odin P, Chaudhuri KR, Slevin JT et al (2015) Collective physician perspectives on non-oral medication approaches for the management of clinically relevant unresolved issues in Parkinson’s disease: Consensus from an international survey and discussion program. Parkinsonism Relat Disord 21:1133–1144. https://doi.org/10.1016/j.parkreldis.2015.07.020 [DOI: 10.1016/j.parkreldis.2015.07.020]
Onofrj M, Thomas A (2005) Acute akinesia in Parkinson disease. Neurology 64:1162–1169. https://doi.org/10.1212/01.wnl.0000157058.17871.7b [DOI: 10.1212/01.wnl.0000157058.17871.7b]
Ou R, Liu H, Hou Y et al (2018) Predictors of camptocormia in patients with Parkinson’s disease: A prospective study from southwest China. Park Relat Disord 52:69–75. https://doi.org/10.1016/j.parkreldis.2018.03.020 [DOI: 10.1016/j.parkreldis.2018.03.020]
Pahwa R, Pagan FL, Kremens DE, Saint-Hilaire M (2023) Clinical use of on-demand therapies for patients with Parkinson’s disease and OFF periods. Neurol Ther 12:1033–1049. https://doi.org/10.1007/s40120-023-00486-5 [DOI: 10.1007/s40120-023-00486-5]
Parkinson J (2002) An essay on the shaking palsy. J Neuropsychiat Clin Neurosci 14:223–236. https://doi.org/10.1176/jnp.14.2.223 [DOI: 10.1176/jnp.14.2.223]
Petry-Schmelzer JN, Krause M, Dembek TA et al (2019) Non-motor outcomes depend on location of neurostimulation in Parkinson’s disease. Brain 142:3592–3604. https://doi.org/10.1093/brain/awz285 [DOI: 10.1093/brain/awz285]
Pfeiffer RF (2018) Gastrointestinal dysfunction in Parkinson’s disease. Curr Treat Options Neurol 20:54. https://doi.org/10.1007/s11940-018-0539-9 [DOI: 10.1007/s11940-018-0539-9]
Pfister FMJ, Um TT, Pichler DC et al (2020) High-resolution motor state detection in Parkinson’s disease using convolutional neural networks. Sci Rep 10:5860. https://doi.org/10.1038/s41598-020-61789-3 [DOI: 10.1038/s41598-020-61789-3]
Pirker W, Katzenschlager R, Hallett M, Poewe W (2023) Pharmacological treatment of tremor in Parkinson’s disease revisited. J Park’s Dis 13:127–144. https://doi.org/10.3233/jpd-225060 [DOI: 10.3233/jpd-225060]
Poewe W, Seppi K, Tanner CM et al (2017) Parkinson disease. Nat Rev Dis Prim 3:17013. https://doi.org/10.1038/nrdp.2017.13 [DOI: 10.1038/nrdp.2017.13]
Pötter-Nerger M, Löhle M, Höglinger G, Poewe W, Group GPG (2024) Akinetic crisis and withdrawal syndromes: guideline “Parkinson’s disease” of the German Society of Neurology. J Neurol 271:6485–6493. https://doi.org/10.1007/s00415-024-12649-x [DOI: 10.1007/s00415-024-12649-x]
Pürner D, Hormozi M, Weiß D et al (2023) Nationwide retrospective analysis of combinations of advanced therapies in patients with Parkinson disease. Neurology 101:e2078–e2093. https://doi.org/10.1212/wnl.0000000000207858 [DOI: 10.1212/wnl.0000000000207858]
Rabinak CA, Nirenberg MJ (2010) Dopamine agonist withdrawal syndrome in Parkinson disease. Arch Neurol 67:58–63. https://doi.org/10.1001/archneurol.2009.294 [DOI: 10.1001/archneurol.2009.294]
Reese R, Koeglsperger T, Schrader C et al (2025) Invasive therapies for Parkinson’s disease: an adapted excerpt from the guidelines of the German Society of Neurology. J Neurol 272:219. https://doi.org/10.1007/s00415-025-12915-6 [DOI: 10.1007/s00415-025-12915-6]
Reuter I, Ellis CM, Chaudhuri KR (1999) Nocturnal subcutaneous apomorphine infusion in Parkinson’s disease and restless legs syndrome. Acta Neurol Scand 100:163–167. https://doi.org/10.1111/j.1600-0404.1999.tb00732.x [DOI: 10.1111/j.1600-0404.1999.tb00732.x]
Ricciardi L, Bove F, Espay KJ et al (2016) 24-Hour infusion of levodopa/carbidopa intestinal gel for nocturnal akinesia in advanced Parkinson’s disease. Mov Disord 31:597–598. https://doi.org/10.1002/mds.26564 [DOI: 10.1002/mds.26564]
Rieu I, Houeto JL, Pereira B et al (2016) Impact of mood and behavioral disorders on quality of life in Parkinson’s disease. J Park’s Dis 6:267–277. https://doi.org/10.3233/jpd-150747 [DOI: 10.3233/jpd-150747]
Rosebraugh M, Liu W, Neenan M, Facheris MF (2021) Foslevodopa/Foscarbidopa is well tolerated and maintains stable levodopa and carbidopa exposure following subcutaneous infusion. J Park’s Dis 11:1695–1702. https://doi.org/10.3233/jpd-212813 [DOI: 10.3233/jpd-212813]
Rosebraugh M, Stodtmann S, Liu W, Facheris MF (2022) Foslevodopa/foscarbidopa subcutaneous infusion maintains equivalent levodopa exposure to levodopa-carbidopa intestinal gel delivered to the jejunum. Parkinsonism Relat D 97:68–72. https://doi.org/10.1016/j.parkreldis.2022.03.012 [DOI: 10.1016/j.parkreldis.2022.03.012]
Rossi P, Colosimo C, Moro E et al (2000) Acute challenge with apomorphine and levodopa in parkinsonism. Eur Neurol 43:95–101. https://doi.org/10.1159/000008142 [DOI: 10.1159/000008142]
Santos-García D, López-Manzanares L, Muro I et al (2025) Effectiveness and safety of levodopa–entacapone–carbidopa infusion in Parkinson disease: A real-world data study. Eur J Neurol 32:e16535. https://doi.org/10.1111/ene.16535 [DOI: 10.1111/ene.16535]
Schröter N, Sajonz BEA, Jost WH et al (2024) Advanced therapies in Parkinson’s disease: an individualized approach to their indication. J Neural Transm 131:1285–1293. https://doi.org/10.1007/s00702-024-02773-3 [DOI: 10.1007/s00702-024-02773-3]
Seppi K, Chaudhuri KR, Coelho M et al (2019) Update on treatments for nonmotor symptoms of Parkinson’s disease—an evidence-based medicine review. Mov Disord 34:180–198. https://doi.org/10.1002/mds.27602 [DOI: 10.1002/mds.27602]
Soileau MJ, Aldred J, Budur K et al (2022) Safety and efficacy of continuous subcutaneous foslevodopa-foscarbidopa in patients with advanced Parkinson’s disease: a randomised, double-blind, active-controlled, phase 3 trial. Lancet Neurol 21:1099–1109. https://doi.org/10.1016/s1474-4422(22)00400-8 [DOI: 10.1016/s1474-4422(22)00400-8]
Spada F, Barnes TM, Greive KA (2018) Comparative safety and efficacy of topical mometasone furoate with other topical corticosteroids. Australas J Dermatol 59:e168–e174. https://doi.org/10.1111/ajd.12762 [DOI: 10.1111/ajd.12762]
Standaert DG, Aldred J, Anca-Herschkovitsch M et al (2021) DUOGLOBE: one-year outcomes in a real-world study of levodopa carbidopa intestinal gel for Parkinson’s disease. Mov Disord Clin Pract 8:1061–1074. https://doi.org/10.1002/mdc3.13239 [DOI: 10.1002/mdc3.13239]
Stocchi F, Antonini A, Barone P et al (2014) Early DEtection of wEaring off in Parkinson disease: The DEEP study. Park Relat Disord 20:204–211. https://doi.org/10.1016/j.parkreldis.2013.10.027 [DOI: 10.1016/j.parkreldis.2013.10.027]
Storch A, Schneider CB, Wolz M et al (2013) Nonmotor fluctuations in Parkinson disease. Neurology 80:800–809. https://doi.org/10.1212/wnl.0b013e318285c0ed [DOI: 10.1212/wnl.0b013e318285c0ed]
Takubo H, Harada T, Hashimoto T et al (2003) A collaborative study on the malignant syndrome in Parkinson’s disease and related disorders. Park Relat Disord 9:31–41. https://doi.org/10.1016/s1353-8020(02)00122-0 [DOI: 10.1016/s1353-8020(02)00122-0]
Thomas A, Onofrj M (2005) Akinetic crisis, acute akinesia, neuroleptic malignant-like syndrome, Parkinsonism–hyperpyrexia syndrome, and malignant syndrome are the same entity and are often independent of treatment withdrawal. Mov Disord 20:1671–1671. https://doi.org/10.1002/mds.20689 [DOI: 10.1002/mds.20689]
Timpka J, Henriksen T, Odin P (2016) Non-oral continuous drug delivery techniques in Parkinson’s disease: for whom, when, and how? Mov Disord Clin Pract 3:221–229. https://doi.org/10.1002/mdc3.12303 [DOI: 10.1002/mdc3.12303]
Todorova A, Chaudhuri KR (2013) Subcutaneous apomorphine and non-motor symptoms in Parkinson’s disease. Park Relat Disord 19:1073–1078. https://doi.org/10.1016/j.parkreldis.2013.08.012 [DOI: 10.1016/j.parkreldis.2013.08.012]
Wang J-Y, Huang J-F, Zhu S-G et al (2022) Parkinsonism-hyperpyrexia syndrome and dyskinesia-hyperpyrexia syndrome in Parkinson’s disease: two cases and literature review. J Park’s Dis 12:1727–1735. https://doi.org/10.3233/jpd-223362 [DOI: 10.3233/jpd-223362]
Weaver F, Follett K, Hur K et al (2005) Deep brain stimulation in Parkinson disease: a metaanalysis of patient outcomes. J Neurosurg 103:956–967. https://doi.org/10.3171/jns.2005.103.6.0956 [DOI: 10.3171/jns.2005.103.6.0956]
Weaver FM, Follett KA, Stern M et al (2012) Randomized trial of deep brain stimulation for Parkinson disease: thirty-six-month outcomes. Neurology 79:55–65. https://doi.org/10.1212/wnl.0b013e31825dcdc1 [DOI: 10.1212/wnl.0b013e31825dcdc1]
Weise D, Haferkamp S (2025) Neutrophil-rich infusion site reactions after continuous subcutaneous application of Foslevodopa/Foscarbidopa. Mov Disord. https://doi.org/10.1002/mds.30121 [DOI: 10.1002/mds.30121]
Winter Y, von Campenhausen S, Arend M et al (2011) Health-related quality of life and its determinants in Parkinson’s disease: Results of an Italian cohort study. Park Relat Disord 17:265–269. https://doi.org/10.1016/j.parkreldis.2011.01.003 [DOI: 10.1016/j.parkreldis.2011.01.003]
Witjas T, Kaphan E, Azulay JP et al (2002) Nonmotor fluctuations in Parkinson’s disease. Neurology 59:408–413. https://doi.org/10.1212/wnl.59.3.408 [DOI: 10.1212/wnl.59.3.408]
Xie H, Zhang Q, Jiang Y et al (2022) Parkinson’s disease with mild cognitive impairment may has a lower risk of cognitive decline after subthalamic nucleus deep brain stimulation: A retrospective cohort study. Front Hum Neurosci 16:943472. https://doi.org/10.3389/fnhum.2022.943472 [DOI: 10.3389/fnhum.2022.943472]
Yoshihara N, Nishikawa N, Watanabe R, Hattori N (2024) Skin inflammatory reactions in patients with continuous subcutaneous injection of Foslevodopa-Foscarbidopa hydrate: histopathology. Mov Disord. https://doi.org/10.1002/mds.30069 [DOI: 10.1002/mds.30069]
Journal Article

Word Cloud

Similar Articles

Cited By